Clinical Research Directory
Browse clinical research sites, groups, and studies.
AMG 510 Ethnic Sensitivity Study (CodeBreaK 105).
Sponsor: Amgen
Summary
To evaluate safety, tolerability, PK, and preliminary efficacy of AMG 510 PO QD in subjects of Chinese descent with KRAS p.G12C-mutant advanced/metastatic solid tumors.
Official title: A Phase 1, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 in Subjects of Chinese Descent With Advanced/Metastatic Solid Tumors With KRAS p.G12C Mutation (CodeBreaK 105)
Key Details
Gender
All
Age Range
18 Years - 100 Years
Study Type
INTERVENTIONAL
Enrollment
12
Start Date
2020-04-28
Completion Date
2026-02-09
Last Updated
2026-05-06
Healthy Volunteers
No
Interventions
AMG 510
Subjects will be enrolled and will receive AMG 510 PO QD.
Locations (4)
University of Hong Kong, Queen Mary Hospital
Hong Kong, Hong Kong
Prince of Wales Hospital
Shatin, New Territories, Hong Kong
Veterans General Hospital - Taichung
Taichung, Taiwan
National Taiwan University Hospital
Taipei, Taiwan